HOME > Investors > Events & Presentations
Subject 2019 J.P Morgan Global Healthcare Conference
Writer ViroMed
Date 2018/12/19

ViroMed to Present at the 37th Annual J.P. Morgan Healthcare Conference


Dec 19, 2018 - Seoul, Korea - ViroMed Co. Ltd. (084990:KS) dba VM BioPharma has been invited to present at the 37th J.P. Morgan Healthcare Conference, from 7th to 10th January in San Francisco, the biggest and most prestigious investor relations event of the year in the healthcare industry.

    Sunyoung Kim, DPhil, CEO on January 9th will give a presentation focusing on the company’s late stage clinical programs, specifically its flagship product VM202, and other product candidates in the pipeline. VM202 is a novel gene therapy medicine based on the company’s proprietary plasmid DNA platform and its Phase III clincial trial for diabetic peripheral neuropaty is expecting its top-line data early May 2019.

    “Being officially invited as a speaker to this event, I am very excited to present VM202 to the global audience from the industy and the investor community. This I am sure will be an opportunity that boosts the global market potential of VM202,” commented Dr. Sunyoung Kim. 


Presentation material will be available at www.viromed21.com following the Conference.


  ※ ViroMed Presentation
      - Where: the 37th Annual J.P. Morgan Healthcare Conference 
      - Who: Sunyoung Kim, DPhil, CEO
      - When: Wednesday, January 9th, 2019 at 11:30 AM PST

About VM202
VM202, donaperminogene seltoplasmid, is a proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms needed for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wild-type human HGF proteins.
When introduced into the body, HGF protein is expressed from VM202 and induces the formation of new blood vessels, suppresses levels of selective pain mediators, supports regeneration/repair of damaged peripheral nerves, and ameliorates atrophic condition of skeletal muscle.

About ViroMed Co., Ltd. and VM BioPharma
VM BioPharma is the US division of ViroMed Co., Ltd. which develops new and innovative biopharmaceuticals based upon its multiple proprietary scientific platform technologies to meet unmet medical needs. Currently, the company is actively focusing on developing its lead product, plasmid DNA-based drug VM202, at various clinical stages in the U.S., Korea, and China, for cardiovascular and neurological diseases, including PDPN, diabetic foot ulcer (DFU), amyotrophic lateral sclerosis (ALS) and ischemic heart disease (IHD). Visit viromed21.com.

Forward-Looking Statements
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions, and projections, and speak only as of the date they are made. ViroMed undertakes no obligation to update any forward-looking statement considering new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond the control of the company. Actual results or outcomes may differ materially from those implied by the forward-looking statements because of the impact of a number of factors, many of which are made public in more detail through the company’s corporate public announcement in compliance with the Financial Investment Services and Capital Markets Act of the Republic of Korea. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.